nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.10.2009 | Original Paper

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

verfasst von: Guan Zhen Yu, Ying Chen, Jie Jun Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Growth factor receptor-bound 2 (Grb2)-mediated HER2 signaling is thought to play a critical role in gastric cancer development, progression and metastasis. However, little is known about their expression in gastric cancer. In this study, we try to explore their relationship with clinicopathological parameters and prognostic significance in gastric cancer patients.

Materials and methods

We examined the expression of Grb2 and HER2 in normal gastric mucosa, primary gastric cancers, and lymph node metastases using immunohistochemical analysis of tissue microarrays containing specimens obtained from 1,143 patients with gastric cancer.

Results

Grb2 was overexpressed in 48% (553/1,143) of primary tumors and 59% (155/262) of lymph node metastases. We observed significant differences in Grb2 expression between the primary tumors and the lymph node metastases (P < 0.01). Also, HER2 was overexpressed in 28% (321/1,143) of the primary tumors and 30% (79/262) of the lymph node metastases. Overexpression of Grb2 and Her2 was associated with age (>60 years), tumor location (cardia of stomach), adenocarcinoma, and high/moderate differentiation. A significant relationship was found between Grb2 and HER2 expression using Chi-Square Tests and Spearman Correlation. Overexpression of Grb2 correlated significantly with poor survival rates in both univariate and multivariate analysis.

Conclusions

Our data demonstrated a progressive amplification of Grb2 and HER2 expression in gastric carcinogenesis, suggesting the importance of Grb2 and HER2 as positive biomarkers for gastric cancer development and progression.

Bianco R, Melisi D, Ciardiello F et al (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 42:290–294. doi:10.1016/j.ejca.2005.07.034 CrossRefPubMed

Blok P, Craanen ME, Dekker W et al (1998) No evidence for c-erbB-2 overexpression in gastric carcinogenesis. Histopathology 32:335–339. doi:10.1046/j.1365-2559.1998.00376.x CrossRefPubMed

Bose S, Chandran S, Mirocha JM et al (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19:238–245. doi:10.1038/modpathol.3800525 CrossRefPubMed

Cantley LC, Auger KR, Carpenter C et al (1991) Oncogenes and signal transduction. Cell 64:281–302. doi:10.1016/0092-8674(91)90639-G CrossRefPubMed

Chardin P, Cussac D, Maignan S et al (1995) The Grb2 adaptor. FEBS Lett 369:47–51. doi:10.1016/0014-5793(95)00578-W CrossRefPubMed

Cheng AM, Saxton TM, Sakai R et al (1998) Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95:793–803. doi:10.1016/S0092-8674(00)81702-X CrossRefPubMed

D’Ambrosio C, Hongo A, Li S et al (1996) The role of Grb2 in the growth and transformation of mouse embryo cells. Oncogene 12:371–378PubMed

Dharmawardana PG, Peruzzi B, Giubellino A et al (2006) Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs 17:13–20. doi:10.1097/01.cad.0000185180.72604.ac CrossRefPubMed

Downward J (1994) The GRB2/Sem-5 adaptor protein. FEBS Lett 338:113–117. doi:10.1016/0014-5793(94)80346-3 CrossRefPubMed

Ghaderi A, Vasei M, Maleck-Hosseini SA et al (2002) The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 8:252–256CrossRefPubMed

Half E, Broaddus R, Danenberg KD et al (2004) HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108:540–548. doi:10.1002/ijc.11599 CrossRefPubMed

Ischenko I, Petrenko O, Gu H et al (2003) Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase. Oncogene 22:6311–6318. doi:10.1038/sj.onc.1206742 CrossRefPubMed

Janes PW, Daly RJ, deFazio A et al (1994) Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 9:3601–3608PubMed

Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139–152. doi:10.1097/00019606-200109000-00001 CrossRefPubMed

Leng J, Lang J, Shen K et al (1997) Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J 12:67–70PubMed

Lowenstein EJ, Daly RJ, Batzer AG et al (1992) The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431–442. doi:10.1016/0092-8674(92)90167-B CrossRefPubMed

MacFarlane R, Speers C, Masoudi H et al (2008) Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26:abstr 1000

McCulloch P, Taggart T, Ochiai A et al (1997) c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol 23:304–309. doi:10.1016/S0748-7983(97)90669-7 CrossRefPubMed

Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487. doi:10.1038/sj.onc.1210477 CrossRefPubMed

Motojima K, Furui J, Kohara N et al (1994) erbB-2 Expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 115:349–354PubMed

Oshima CT, Lanzoni VP, Iriya K et al (2001) C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. Int J Biol Markers 16:250–254PubMed

Pinto-de-Sousa J, David L, Almeida R et al (2002) c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 10:247–256. doi:10.1177/106689690201000402 CrossRefPubMed

Potrc S, Gadiijev E, Hajdinjak T et al (2007) Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer. Hepatogastroenterology 54:308–314PubMed

Roder DM (2002) The epidemiology of gastric cancer. Gastric Cancer 5(Suppl 1):5–11. doi:10.1007/s10120-002-0203-6 CrossRefPubMed

Saucier C, Papavasiliou V, Palazzo A et al (2002) Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis. Oncogene 21:1800–1811. doi:10.1038/sj.onc.1205261 CrossRefPubMed

Schlessinger J, Ullrich A (1992) Growth factor signaling by receptor tyrosine kinases. Neuron 9:383–391. doi:10.1016/0896-6273(92)90177-F CrossRefPubMed

Suzuki T, Tsuda T, Haruma K et al (1995) Growth of human gastric carcinomas and expression of epidermal growth factor, transforming growth factor-alpha, epidermal growth factor receptor and p185c-erbB-2. Oncology 52:385–391CrossRefPubMed

Tateishi M, Toda T, Minamisono Y et al (1992) Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 49:209–212. doi:10.1002/jso.2930490402 CrossRefPubMed

Varis A, Wolf M, Monni O et al (2002) Targets of gene amplification and overexpression at 17q in gastric cancer. Cancer Res 62:2625–2629PubMed

Verbeek BS, Adriaansen-Slot SS, Rijksen G et al (1997) Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol 183:195–203. doi:10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.0.CO;2-Y CrossRefPubMed

Vizoso FJ, Corte MD, Alvarez A et al (2004) Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. Int J Biol Markers 19:268–274PubMed

Wiedmann MW, Caca K (2005) Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5:171–193. doi:10.2174/1568009053765771 CrossRefPubMed

Yano T, Doi T, Ohtsu A et al (2006) Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65–71PubMed

Yao ZJ, King CR, Cao T et al (1999) Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J Med Chem 42:25–35. doi:10.1021/jm980388x CrossRefPubMed

Yip SS, Crew AJ, Gee JM et al (2000) Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer 88:363–368. doi:10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4 CrossRefPubMed

Yokoyama H, Ikehara Y, Kodera Y et al (2006) Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 95:1504–1513. doi:10.1038/sj.bjc.6603459 CrossRefPubMed

Yonemura Y, Ninomiya I, Ohoyama S, et al (1991) Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 67:2914–2918. doi:10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G

Yu GZ, Chen Y, Long YQ et al (2008) New insight into the key proteins and pathways involved in the metastasis of colorectal carcinoma. Oncol Rep 19:1191–1204PubMed

Zang XP, Siwak DR, Nguyen TX et al (2004) KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis 21:437–443. doi:10.1007/s10585-004-2051-8 CrossRefPubMed

Titel: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance
verfasst von: Guan Zhen Yu
Ying Chen
Jie Jun Wang
Publikationsdatum: 01.10.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0574-8

Springer Medizin

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

Abstract

Purpose

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2009

RETRACTED ARTICLE: Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer

The antiangiogenic effects of tyroservatide on animal models of hepatocellular carcinoma

High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma

ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma

Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie